SubsidieMeestersAutomated retinal scans for early detection of diabetic eye diseases through use of artificial intelligence
Oivi aims to enhance accessibility to affordable eye care by developing a low-cost, automated retinal imaging device for early detection of diabetic retinopathy, preventing blindness in millions.
Projectdetails
Introduction
Oivi provides affordable eye care for all and prevents unnecessary blindness by providing a low-cost camera for retinal (fundus) photography, with fully automated image capture and diagnostics.
Problem Statement
Oivi is a point-of-care device for eye screening of diabetic retinopathy (DR). DR affects over 160 million people worldwide and is the most common cause of blindness among working-age adults. Yet, early detection can successfully prevent vision loss in 95% of the cases.
Current Challenges
Current solutions for DR screening are expensive and require extensive training, which limits accessibility to patients, especially in developing countries.
Oivi Solution
Oivi is a unique combination of:
- Automated
- Easy-to-use
- Low-cost
- Integrated Machine Learning/Artificial Intelligence solutions (for image capturing and DR diagnostics)
- Highly portable design
Project Goals
Within the iScan project, we want to:
- Mature the device and its diagnostic functionalities
- Clinically validate our solution
- Assure regulatory approvals
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.622.500 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- OIVI ASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
AI-based software for digital drug testingEyescanner is an AI-based software that detects drug influence through eye analysis, aiming to reduce accidents by integrating with existing technology in various environments. | EIC Accelerator | € 2.456.775 | 2023 | Details |
iLoF: AI-augmented photonics to identify and quantify disease biomarkersiLoF is developing an AI-driven platform to create a personalized drug discovery tool for Alzheimer’s disease by analyzing biological samples for patient-specific signatures. | EIC Accelerator | € 2.495.850 | 2023 | Details |
OMI AI ECG Model - application for more accurate heart attack diagnosisThe OMI AI ECG Model is an AI mobile app that enhances OMI diagnosis from ECGs, improving sensitivity and speed, ultimately transforming heart attack management and saving lives. | EIC Accelerator | € 2.499.999 | 2024 | Details |
AI-based software for digital drug testing
Eyescanner is an AI-based software that detects drug influence through eye analysis, aiming to reduce accidents by integrating with existing technology in various environments.
iLoF: AI-augmented photonics to identify and quantify disease biomarkers
iLoF is developing an AI-driven platform to create a personalized drug discovery tool for Alzheimer’s disease by analyzing biological samples for patient-specific signatures.
OMI AI ECG Model - application for more accurate heart attack diagnosis
The OMI AI ECG Model is an AI mobile app that enhances OMI diagnosis from ECGs, improving sensitivity and speed, ultimately transforming heart attack management and saving lives.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared careI(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care. | EIC Pathfinder | € 3.454.613 | 2024 | Details |
Haalbaarheid van bevolkingsonderzoek met behulp van kunstmatige intelligentieHet project ontwikkelt een AI-gebaseerde dienst voor vroegtijdige glaucoomdetectie om kosten te verlagen en de impact van blindheid te beperken door bevolkingsonderzoek te verbeteren. | Mkb-innovati... | € 19.472 | 2023 | Details |
Totaaloplossing voor anderhalvelijnszorg bij oogaandoeningenHet project ontwikkelt een DRP-platform en gebruiksvriendelijke funduscamera om oogscreening te verbeteren, waardoor huisartsen zelf kunnen screenen en wachttijden voor oogzorg verminderen. | Mkb-innovati... | € 198.205 | 2021 | Details |
Visual Impairment Screening using Images from Ophthalmology and Novel pathways for Structural Analysis and Fast EvaluationVISIONSAFE aims to enhance early detection of preventable eye diseases by extracting and analyzing macro- and microstructural biomarkers from clinical eye images using advanced data science techniques. | ERC Starting... | € 1.497.873 | 2025 | Details |
OogVoHolland AI en Laméris ontwikkelen een AI-gestuurd point-of-care product voor snellere en goedkopere diagnose van oogafwijkingen, met focus op diabetische retinopathie. | Mkb-innovati... | € 124.363 | 2020 | Details |
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care.
Haalbaarheid van bevolkingsonderzoek met behulp van kunstmatige intelligentie
Het project ontwikkelt een AI-gebaseerde dienst voor vroegtijdige glaucoomdetectie om kosten te verlagen en de impact van blindheid te beperken door bevolkingsonderzoek te verbeteren.
Totaaloplossing voor anderhalvelijnszorg bij oogaandoeningen
Het project ontwikkelt een DRP-platform en gebruiksvriendelijke funduscamera om oogscreening te verbeteren, waardoor huisartsen zelf kunnen screenen en wachttijden voor oogzorg verminderen.
Visual Impairment Screening using Images from Ophthalmology and Novel pathways for Structural Analysis and Fast Evaluation
VISIONSAFE aims to enhance early detection of preventable eye diseases by extracting and analyzing macro- and microstructural biomarkers from clinical eye images using advanced data science techniques.
OogVo
Holland AI en Laméris ontwikkelen een AI-gestuurd point-of-care product voor snellere en goedkopere diagnose van oogafwijkingen, met focus op diabetische retinopathie.